New combo pill aims to crush stubborn high cholesterol

NCT ID NCT07442630

Ongoing Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a fixed-dose combination pill containing Pitavastatin and Ezetimibe against Pitavastatin alone in 88 people with high cholesterol and high triglycerides. Participants take the pill daily for 52 weeks. The main goal is to see how much LDL ('bad') cholesterol drops after 8 weeks, with longer-term effects on HDL and triglycerides also measured.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pitavastatin and Ezetimibe combination pill
What this could lead to: If successful, this could provide a more effective long-term option for managing high cholesterol and reducing heart disease risk.
What could go wrong: This is a Phase 4 study, so the drugs are already approved; the main uncertainties are about long-term safety and whether the combination works better than Pitavastatin alone. Side effects like muscle pain or liver issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLEMIA

Contacts and locations

Locations

The Catholic University of Korea, Yeouido St. Mary's Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.